Protein Arginine Deiminase

蛋白精氨酸脱亚胺酶 (PAD) 是一组钙依赖性酶,在瓜氨酸化过程中起着至关重要的作用,可以催化精氨酸残基转化为瓜氨酸。该化学反应诱导瓜氨酸化蛋白的形成,导致结构和功能发生改变,从而导致多种病理疾病,包括炎症和自身免疫性疾病。这些病理将 PAD 确立为治疗靶点,并且已知有多种 PAD 抑制剂。

人类编码了五种 PAD,称为 PAD 1-4 和 PAD6。在五种 PAD 同工酶(PAD1、2、3、4 和 6)中,只有四种(PADs1-4)具有催化活性。PAD 活性受 Ca2+ 严格调控,PAD 含有 4 个 (PAD1)、5 个 (PAD3、4) 或 6 个 (PAD2) Ca2+ 结合位点。PAD 活性失调(最显著的是 PAD2 和 PAD4)与多种炎症性疾病(例如类风湿性关节炎)以及癌症有关,而 PAD 抑制剂(例如 Cl-amidine 和 BB-Cl-amidine)在多种临床前动物疾病模型中均显示出疗效。

Protein arginine deiminase (PAD), is a group of calcium-dependent enzymes, which play crucial roles in citrullination, and can catalyze arginine residues into citrulline. his chemical reaction induces citrullinated proteins formation with altered structure and function, leading to numerous pathological diseases, including inflammation and autoimmune diseases. These pathologies established the PADs as therapeutic targets and multiple PAD inhibitors are known.

Humans encode five PADs, designated PADs 1-4 and PAD6. Of the five PAD isozymes (PAD1, 2, 3, 4 and 6), only four (PADs1-4) are catalytically active. PAD activity is tightly regulated by Ca2+ and PADs contain 4 (PAD1), 5 (PAD3, 4) or 6 (PAD2) Ca2+-binding sites. Dysregulated PAD activity, most notably PAD2 and PAD4, is associated with multiple inflammatory diseases (e.g., rheumatoid arthritis) as well as cancer, and PAD inhibitors, such as Cl-amidine and BB-Cl-amidine, show efficacy in multiple preclinical animal models of disease.

共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
PADI4_7

PADI4_7 是一种肽基精氨酸脱亚胺酶 IV (PADI4) 惰性结合剂,Kd 值为 8 nM,可结合 PADI4 但不调控其催化活性,并可被功能化为生物素化探针 (bio-PADI4_7),该探针能从细胞提取物中富集细胞内 PADI4 以用于生化分析,包括鉴定静息或激活条件下的 PADI4 相互作用蛋白。

Ligand
PADI4_7

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础